Global Dendritic Cell Cancer Vaccine Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028
The Dendritic Cell Cancer Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Dendritic Cell Cancer Vaccine market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Pediatrics accounting for % of the Dendritic Cell Cancer Vaccine global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While CreaVax segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Dendritic Cell Cancer Vaccine include Activarti, Argos Therapeutics, SOTIO (Acquired by PPF Group), Bellicum Pharmaceuticals, and JW CreaGene, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Dendritic Cell Cancer Vaccine market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
CreaVax
Sipuleucel-T (Provenge)
Others
Market segment by Application can be divided into
Pediatrics
Adults
The key market players for global Dendritic Cell Cancer Vaccine market are listed below:
Activarti
Argos Therapeutics
SOTIO (Acquired by PPF Group)
Bellicum Pharmaceuticals
JW CreaGene
DanDrit
DCPrime
Elios Therapeutics
ImmunoCellular Therapeutics
Kiromic
Medigene
Merck
Northwest Biotherapeutics
Immutep Limited
Dendreon Corporation
Oncobiomed
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Dendritic Cell Cancer Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Dendritic Cell Cancer Vaccine, with price, sales, revenue and global market share of Dendritic Cell Cancer Vaccine from 2019 to 2022.
Chapter 3, the Dendritic Cell Cancer Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Dendritic Cell Cancer Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Dendritic Cell Cancer Vaccine market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Dendritic Cell Cancer Vaccine.
Chapter 13, 14, and 15, to describe Dendritic Cell Cancer Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Dendritic Cell Cancer Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Dendritic Cell Cancer Vaccine Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 CreaVax
1.2.3 Sipuleucel-T (Provenge)
1.2.4 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Dendritic Cell Cancer Vaccine Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Pediatrics
1.3.3 Adults
1.4 Global Dendritic Cell Cancer Vaccine Market Size & Forecast
1.4.1 Global Dendritic Cell Cancer Vaccine Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Dendritic Cell Cancer Vaccine Sales in Volume (2017-2028)
1.4.3 Global Dendritic Cell Cancer Vaccine Price (2017-2028)
1.5 Global Dendritic Cell Cancer Vaccine Production Capacity Analysis
1.5.1 Global Dendritic Cell Cancer Vaccine Total Production Capacity (2017-2028)
1.5.2 Global Dendritic Cell Cancer Vaccine Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Dendritic Cell Cancer Vaccine Market Drivers
1.6.2 Dendritic Cell Cancer Vaccine Market Restraints
1.6.3 Dendritic Cell Cancer Vaccine Trends Analysis
2 Manufacturers Profiles
2.1 Activarti
2.1.1 Activarti Details
2.1.2 Activarti Major Business
2.1.3 Activarti Dendritic Cell Cancer Vaccine Product and Services
2.1.4 Activarti Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Argos Therapeutics
2.2.1 Argos Therapeutics Details
2.2.2 Argos Therapeutics Major Business
2.2.3 Argos Therapeutics Dendritic Cell Cancer Vaccine Product and Services
2.2.4 Argos Therapeutics Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 SOTIO (Acquired by PPF Group)
2.3.1 SOTIO (Acquired by PPF Group) Details
2.3.2 SOTIO (Acquired by PPF Group) Major Business
2.3.3 SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Product and Services
2.3.4 SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Bellicum Pharmaceuticals
2.4.1 Bellicum Pharmaceuticals Details
2.4.2 Bellicum Pharmaceuticals Major Business
2.4.3 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Product and Services
2.4.4 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 JW CreaGene
2.5.1 JW CreaGene Details
2.5.2 JW CreaGene Major Business
2.5.3 JW CreaGene Dendritic Cell Cancer Vaccine Product and Services
2.5.4 JW CreaGene Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 DanDrit
2.6.1 DanDrit Details
2.6.2 DanDrit Major Business
2.6.3 DanDrit Dendritic Cell Cancer Vaccine Product and Services
2.6.4 DanDrit Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 DCPrime
2.7.1 DCPrime Details
2.7.2 DCPrime Major Business
2.7.3 DCPrime Dendritic Cell Cancer Vaccine Product and Services
2.7.4 DCPrime Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Elios Therapeutics
2.8.1 Elios Therapeutics Details
2.8.2 Elios Therapeutics Major Business
2.8.3 Elios Therapeutics Dendritic Cell Cancer Vaccine Product and Services
2.8.4 Elios Therapeutics Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 ImmunoCellular Therapeutics
2.9.1 ImmunoCellular Therapeutics Details
2.9.2 ImmunoCellular Therapeutics Major Business
2.9.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Product and Services
2.9.4 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Kiromic
2.10.1 Kiromic Details
2.10.2 Kiromic Major Business
2.10.3 Kiromic Dendritic Cell Cancer Vaccine Product and Services
2.10.4 Kiromic Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Medigene
2.11.1 Medigene Details
2.11.2 Medigene Major Business
2.11.3 Medigene Dendritic Cell Cancer Vaccine Product and Services
2.11.4 Medigene Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Merck
2.12.1 Merck Details
2.12.2 Merck Major Business
2.12.3 Merck Dendritic Cell Cancer Vaccine Product and Services
2.12.4 Merck Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Northwest Biotherapeutics
2.13.1 Northwest Biotherapeutics Details
2.13.2 Northwest Biotherapeutics Major Business
2.13.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Product and Services
2.13.4 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 Immutep Limited
2.14.1 Immutep Limited Details
2.14.2 Immutep Limited Major Business
2.14.3 Immutep Limited Dendritic Cell Cancer Vaccine Product and Services
2.14.4 Immutep Limited Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15 Dendreon Corporation
2.15.1 Dendreon Corporation Details
2.15.2 Dendreon Corporation Major Business
2.15.3 Dendreon Corporation Dendritic Cell Cancer Vaccine Product and Services
2.15.4 Dendreon Corporation Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16 Oncobiomed
2.16.1 Oncobiomed Details
2.16.2 Oncobiomed Major Business
2.16.3 Oncobiomed Dendritic Cell Cancer Vaccine Product and Services
2.16.4 Oncobiomed Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Dendritic Cell Cancer Vaccine Breakdown Data by Manufacturer
3.1 Global Dendritic Cell Cancer Vaccine Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Dendritic Cell Cancer Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Dendritic Cell Cancer Vaccine
3.4 Market Concentration Rate
3.4.1 Top 3 Dendritic Cell Cancer Vaccine Manufacturer Market Share in 2021
3.4.2 Top 6 Dendritic Cell Cancer Vaccine Manufacturer Market Share in 2021
3.5 Global Dendritic Cell Cancer Vaccine Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Dendritic Cell Cancer Vaccine Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Dendritic Cell Cancer Vaccine Market Size by Region
4.1.1 Global Dendritic Cell Cancer Vaccine Sales in Volume by Region (2017-2028)
4.1.2 Global Dendritic Cell Cancer Vaccine Revenue by Region (2017-2028)
4.2 North America Dendritic Cell Cancer Vaccine Revenue (2017-2028)
4.3 Europe Dendritic Cell Cancer Vaccine Revenue (2017-2028)
4.4 Asia-Pacific Dendritic Cell Cancer Vaccine Revenue (2017-2028)
4.5 South America Dendritic Cell Cancer Vaccine Revenue (2017-2028)
4.6 Middle East and Africa Dendritic Cell Cancer Vaccine Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Dendritic Cell Cancer Vaccine Sales in Volume by Type (2017-2028)
5.2 Global Dendritic Cell Cancer Vaccine Revenue by Type (2017-2028)
5.3 Global Dendritic Cell Cancer Vaccine Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Dendritic Cell Cancer Vaccine Sales in Volume by Application (2017-2028)
6.2 Global Dendritic Cell Cancer Vaccine Revenue by Application (2017-2028)
6.3 Global Dendritic Cell Cancer Vaccine Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Dendritic Cell Cancer Vaccine Sales by Type (2017-2028)
7.2 North America Dendritic Cell Cancer Vaccine Sales by Application (2017-2028)
7.3 North America Dendritic Cell Cancer Vaccine Market Size by Country
7.3.1 North America Dendritic Cell Cancer Vaccine Sales in Volume by Country (2017-2028)
7.3.2 North America Dendritic Cell Cancer Vaccine Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Dendritic Cell Cancer Vaccine Sales by Type (2017-2028)
8.2 Europe Dendritic Cell Cancer Vaccine Sales by Application (2017-2028)
8.3 Europe Dendritic Cell Cancer Vaccine Market Size by Country
8.3.1 Europe Dendritic Cell Cancer Vaccine Sales in Volume by Country (2017-2028)
8.3.2 Europe Dendritic Cell Cancer Vaccine Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Dendritic Cell Cancer Vaccine Sales by Type (2017-2028)
9.2 Asia-Pacific Dendritic Cell Cancer Vaccine Sales by Application (2017-2028)
9.3 Asia-Pacific Dendritic Cell Cancer Vaccine Market Size by Region
9.3.1 Asia-Pacific Dendritic Cell Cancer Vaccine Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Dendritic Cell Cancer Vaccine Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Dendritic Cell Cancer Vaccine Sales by Type (2017-2028)
10.2 South America Dendritic Cell Cancer Vaccine Sales by Application (2017-2028)
10.3 South America Dendritic Cell Cancer Vaccine Market Size by Country
10.3.1 South America Dendritic Cell Cancer Vaccine Sales in Volume by Country (2017-2028)
10.3.2 South America Dendritic Cell Cancer Vaccine Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Dendritic Cell Cancer Vaccine Sales by Type (2017-2028)
11.2 Middle East & Africa Dendritic Cell Cancer Vaccine Sales by Application (2017-2028)
11.3 Middle East & Africa Dendritic Cell Cancer Vaccine Market Size by Country
11.3.1 Middle East & Africa Dendritic Cell Cancer Vaccine Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Dendritic Cell Cancer Vaccine Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Dendritic Cell Cancer Vaccine and Key Manufacturers
12.2 Manufacturing Costs Percentage of Dendritic Cell Cancer Vaccine
12.3 Dendritic Cell Cancer Vaccine Production Process
12.4 Dendritic Cell Cancer Vaccine Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Dendritic Cell Cancer Vaccine Typical Distributors
13.3 Dendritic Cell Cancer Vaccine Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
List of Tables
Table 1. Global Dendritic Cell Cancer Vaccine Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Dendritic Cell Cancer Vaccine Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Activarti Basic Information, Manufacturing Base and Competitors
Table 4. Activarti Major Business
Table 5. Activarti Dendritic Cell Cancer Vaccine Product and Services
Table 6. Activarti Dendritic Cell Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Argos Therapeutics Basic Information, Manufacturing Base and Competitors
Table 8. Argos Therapeutics Major Business
Table 9. Argos Therapeutics Dendritic Cell Cancer Vaccine Product and Services
Table 10. Argos Therapeutics Dendritic Cell Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. SOTIO (Acquired by PPF Group) Basic Information, Manufacturing Base and Competitors
Table 12. SOTIO (Acquired by PPF Group) Major Business
Table 13. SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Product and Services
Table 14. SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Bellicum Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 16. Bellicum Pharmaceuticals Major Business
Table 17. Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Product and Services
Table 18. Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. JW CreaGene Basic Information, Manufacturing Base and Competitors
Table 20. JW CreaGene Major Business
Table 21. JW CreaGene Dendritic Cell Cancer Vaccine Product and Services
Table 22. JW CreaGene Dendritic Cell Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. DanDrit Basic Information, Manufacturing Base and Competitors
Table 24. DanDrit Major Business
Table 25. DanDrit Dendritic Cell Cancer Vaccine Product and Services
Table 26. DanDrit Dendritic Cell Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. DCPrime Basic Information, Manufacturing Base and Competitors
Table 28. DCPrime Major Business
Table 29. DCPrime Dendritic Cell Cancer Vaccine Product and Services
Table 30. DCPrime Dendritic Cell Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Elios Therapeutics Basic Information, Manufacturing Base and Competitors
Table 32. Elios Therapeutics Major Business
Table 33. Elios Therapeutics Dendritic Cell Cancer Vaccine Product and Services
Table 34. Elios Therapeutics Dendritic Cell Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. ImmunoCellular Therapeutics Basic Information, Manufacturing Base and Competitors
Table 36. ImmunoCellular Therapeutics Major Business
Table 37. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Product and Services
Table 38. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Kiromic Basic Information, Manufacturing Base and Competitors
Table 40. Kiromic Major Business
Table 41. Kiromic Dendritic Cell Cancer Vaccine Product and Services
Table 42. Kiromic Dendritic Cell Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Medigene Basic Information, Manufacturing Base and Competitors
Table 44. Medigene Major Business
Table 45. Medigene Dendritic Cell Cancer Vaccine Product and Services
Table 46. Medigene Dendritic Cell Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Merck Basic Information, Manufacturing Base and Competitors
Table 48. Merck Major Business
Table 49. Merck Dendritic Cell Cancer Vaccine Product and Services
Table 50. Merck Dendritic Cell Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Northwest Biotherapeutics Basic Information, Manufacturing Base and Competitors
Table 52. Northwest Biotherapeutics Major Business
Table 53. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Product and Services
Table 54. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 55. Immutep Limited Basic Information, Manufacturing Base and Competitors
Table 56. Immutep Limited Major Business
Table 57. Immutep Limited Dendritic Cell Cancer Vaccine Product and Services
Table 58. Immutep Limited Dendritic Cell Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 59. Dendreon Corporation Basic Information, Manufacturing Base and Competitors
Table 60. Dendreon Corporation Major Business
Table 61. Dendreon Corporation Dendritic Cell Cancer Vaccine Product and Services
Table 62. Dendreon Corporation Dendritic Cell Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 63. Oncobiomed Basic Information, Manufacturing Base and Competitors
Table 64. Oncobiomed Major Business
Table 65. Oncobiomed Dendritic Cell Cancer Vaccine Product and Services
Table 66. Oncobiomed Dendritic Cell Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 67. Global Dendritic Cell Cancer Vaccine Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Doses)
Table 68. Global Dendritic Cell Cancer Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 69. Market Position of Manufacturers in Dendritic Cell Cancer Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 70. Global Dendritic Cell Cancer Vaccine Production Capacity by Company, (K Doses): 2020 VS 2021
Table 71. Head Office and Dendritic Cell Cancer Vaccine Production Site of Key Manufacturer
Table 72. Dendritic Cell Cancer Vaccine New Entrant and Capacity Expansion Plans
Table 73. Dendritic Cell Cancer Vaccine Mergers & Acquisitions in the Past Five Years
Table 74. Global Dendritic Cell Cancer Vaccine Sales by Region (2017-2022) & (K Doses)
Table 75. Global Dendritic Cell Cancer Vaccine Sales by Region (2023-2028) & (K Doses)
Table 76. Global Dendritic Cell Cancer Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 77. Global Dendritic Cell Cancer Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 78. Global Dendritic Cell Cancer Vaccine Sales by Type (2017-2022) & (K Doses)
Table 79. Global Dendritic Cell Cancer Vaccine Sales by Type (2023-2028) & (K Doses)
Table 80. Global Dendritic Cell Cancer Vaccine Revenue by Type (2017-2022) & (USD Million)
Table 81. Global Dendritic Cell Cancer Vaccine Revenue by Type (2023-2028) & (USD Million)
Table 82. Global Dendritic Cell Cancer Vaccine Price by Type (2017-2022) & (USD/Dose)
Table 83. Global Dendritic Cell Cancer Vaccine Price by Type (2023-2028) & (USD/Dose)
Table 84. Global Dendritic Cell Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 85. Global Dendritic Cell Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 86. Global Dendritic Cell Cancer Vaccine Revenue by Application (2017-2022) & (USD Million)
Table 87. Global Dendritic Cell Cancer Vaccine Revenue by Application (2023-2028) & (USD Million)
Table 88. Global Dendritic Cell Cancer Vaccine Price by Application (2017-2022) & (USD/Dose)
Table 89. Global Dendritic Cell Cancer Vaccine Price by Application (2023-2028) & (USD/Dose)
Table 90. North America Dendritic Cell Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
Table 91. North America Dendritic Cell Cancer Vaccine Sales by Country (2023-2028) & (K Doses)
Table 92. North America Dendritic Cell Cancer Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 93. North America Dendritic Cell Cancer Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 94. North America Dendritic Cell Cancer Vaccine Sales by Type (2017-2022) & (K Doses)
Table 95. North America Dendritic Cell Cancer Vaccine Sales by Type (2023-2028) & (K Doses)
Table 96. North America Dendritic Cell Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 97. North America Dendritic Cell Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 98. Europe Dendritic Cell Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
Table 99. Europe Dendritic Cell Cancer Vaccine Sales by Country (2023-2028) & (K Doses)
Table 100. Europe Dendritic Cell Cancer Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 101. Europe Dendritic Cell Cancer Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 102. Europe Dendritic Cell Cancer Vaccine Sales by Type (2017-2022) & (K Doses)
Table 103. Europe Dendritic Cell Cancer Vaccine Sales by Type (2023-2028) & (K Doses)
Table 104. Europe Dendritic Cell Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 105. Europe Dendritic Cell Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 106. Asia-Pacific Dendritic Cell Cancer Vaccine Sales by Region (2017-2022) & (K Doses)
Table 107. Asia-Pacific Dendritic Cell Cancer Vaccine Sales by Region (2023-2028) & (K Doses)
Table 108. Asia-Pacific Dendritic Cell Cancer Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 109. Asia-Pacific Dendritic Cell Cancer Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 110. Asia-Pacific Dendritic Cell Cancer Vaccine Sales by Type (2017-2022) & (K Doses)
Table 111. Asia-Pacific Dendritic Cell Cancer Vaccine Sales by Type (2023-2028) & (K Doses)
Table 112. Asia-Pacific Dendritic Cell Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 113. Asia-Pacific Dendritic Cell Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 114. South America Dendritic Cell Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
Table 115. South America Dendritic Cell Cancer Vaccine Sales by Country (2023-2028) & (K Doses)
Table 116. South America Dendritic Cell Cancer Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 117. South America Dendritic Cell Cancer Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 118. South America Dendritic Cell Cancer Vaccine Sales by Type (2017-2022) & (K Doses)
Table 119. South America Dendritic Cell Cancer Vaccine Sales by Type (2023-2028) & (K Doses)
Table 120. South America Dendritic Cell Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 121. South America Dendritic Cell Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 122. Middle East & Africa Dendritic Cell Cancer Vaccine Sales by Region (2017-2022) & (K Doses)
Table 123. Middle East & Africa Dendritic Cell Cancer Vaccine Sales by Region (2023-2028) & (K Doses)
Table 124. Middle East & Africa Dendritic Cell Cancer Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 125. Middle East & Africa Dendritic Cell Cancer Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 126. Middle East & Africa Dendritic Cell Cancer Vaccine Sales by Type (2017-2022) & (K Doses)
Table 127. Middle East & Africa Dendritic Cell Cancer Vaccine Sales by Type (2023-2028) & (K Doses)
Table 128. Middle East & Africa Dendritic Cell Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 129. Middle East & Africa Dendritic Cell Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 130. Dendritic Cell Cancer Vaccine Raw Material
Table 131. Key Manufacturers of Dendritic Cell Cancer Vaccine Raw Materials
Table 132. Direct Channel Pros & Cons
Table 133. Indirect Channel Pros & Cons
Table 134. Dendritic Cell Cancer Vaccine Typical Distributors
Table 135. Dendritic Cell Cancer Vaccine Typical Customers
List of Figures
Figure 1. Dendritic Cell Cancer Vaccine Picture
Figure 2. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Type in 2021
Figure 3. CreaVax
Figure 4. Sipuleucel-T (Provenge)
Figure 5. Others
Figure 6. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Application in 2021
Figure 7. Pediatrics
Figure 8. Adults
Figure 9. Global Dendritic Cell Cancer Vaccine Revenue, (USD Million) & (K Doses): 2017 & 2021 & 2028
Figure 10. Global Dendritic Cell Cancer Vaccine Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Dendritic Cell Cancer Vaccine Sales (2017-2028) & (K Doses)
Figure 12. Global Dendritic Cell Cancer Vaccine Price (2017-2028) & (USD/Dose)
Figure 13. Global Dendritic Cell Cancer Vaccine Production Capacity (2017-2028) & (K Doses)
Figure 14. Global Dendritic Cell Cancer Vaccine Production Capacity by Geographic Region: 2022 VS 2028
Figure 15. Dendritic Cell Cancer Vaccine Market Drivers
Figure 16. Dendritic Cell Cancer Vaccine Market Restraints
Figure 17. Dendritic Cell Cancer Vaccine Market Trends
Figure 18. Global Dendritic Cell Cancer Vaccine Sales Market Share by Manufacturer in 2021
Figure 19. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Manufacturer in 2021
Figure 20. Dendritic Cell Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 21. Top 3 Dendritic Cell Cancer Vaccine Manufacturer (Revenue) Market Share in 2021
Figure 22. Top 6 Dendritic Cell Cancer Vaccine Manufacturer (Revenue) Market Share in 2021
Figure 23. Global Dendritic Cell Cancer Vaccine Sales Market Share by Region (2017-2028)
Figure 24. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Region (2017-2028)
Figure 25. North America Dendritic Cell Cancer Vaccine Revenue (2017-2028) & (USD Million)
Figure 26. Europe Dendritic Cell Cancer Vaccine Revenue (2017-2028) & (USD Million)
Figure 27. Asia-Pacific Dendritic Cell Cancer Vaccine Revenue (2017-2028) & (USD Million)
Figure 28. South America Dendritic Cell Cancer Vaccine Revenue (2017-2028) & (USD Million)
Figure 29. Middle East & Africa Dendritic Cell Cancer Vaccine Revenue (2017-2028) & (USD Million)
Figure 30. Global Dendritic Cell Cancer Vaccine Sales Market Share by Type (2017-2028)
Figure 31. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Type (2017-2028)
Figure 32. Global Dendritic Cell Cancer Vaccine Price by Type (2017-2028) & (USD/Dose)
Figure 33. Global Dendritic Cell Cancer Vaccine Sales Market Share by Application (2017-2028)
Figure 34. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Application (2017-2028)
Figure 35. Global Dendritic Cell Cancer Vaccine Price by Application (2017-2028) & (USD/Dose)
Figure 36. North America Dendritic Cell Cancer Vaccine Sales Market Share by Type (2017-2028)
Figure 37. North America Dendritic Cell Cancer Vaccine Sales Market Share by Application (2017-2028)
Figure 38. North America Dendritic Cell Cancer Vaccine Sales Market Share by Country (2017-2028)
Figure 39. North America Dendritic Cell Cancer Vaccine Revenue Market Share by Country (2017-2028)
Figure 40. United States Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Canada Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Mexico Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Europe Dendritic Cell Cancer Vaccine Sales Market Share by Type (2017-2028)
Figure 44. Europe Dendritic Cell Cancer Vaccine Sales Market Share by Application (2017-2028)
Figure 45. Europe Dendritic Cell Cancer Vaccine Sales Market Share by Country (2017-2028)
Figure 46. Europe Dendritic Cell Cancer Vaccine Revenue Market Share by Country (2017-2028)
Figure 47. Germany Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. France Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. United Kingdom Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Russia Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Italy Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Asia-Pacific Dendritic Cell Cancer Vaccine Sales Market Share by Region (2017-2028)
Figure 53. Asia-Pacific Dendritic Cell Cancer Vaccine Sales Market Share by Application (2017-2028)
Figure 54. Asia-Pacific Dendritic Cell Cancer Vaccine Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Dendritic Cell Cancer Vaccine Revenue Market Share by Region (2017-2028)
Figure 56. China Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Japan Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Korea Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. India Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Southeast Asia Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Australia Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South America Dendritic Cell Cancer Vaccine Sales Market Share by Type (2017-2028)
Figure 63. South America Dendritic Cell Cancer Vaccine Sales Market Share by Application (2017-2028)
Figure 64. South America Dendritic Cell Cancer Vaccine Sales Market Share by Country (2017-2028)
Figure 65. South America Dendritic Cell Cancer Vaccine Revenue Market Share by Country (2017-2028)
Figure 66. Brazil Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Argentina Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Middle East & Africa Dendritic Cell Cancer Vaccine Sales Market Share by Type (2017-2028)
Figure 69. Middle East & Africa Dendritic Cell Cancer Vaccine Sales Market Share by Application (2017-2028)
Figure 70. Middle East & Africa Dendritic Cell Cancer Vaccine Sales Market Share by Region (2017-2028)
Figure 71. Middle East & Africa Dendritic Cell Cancer Vaccine Revenue Market Share by Region (2017-2028)
Figure 72. Turkey Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Egypt Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. South Africa Dendritic Cell Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Manufacturing Cost Structure Analysis of Dendritic Cell Cancer Vaccine in 2021
Figure 77. Manufacturing Process Analysis of Dendritic Cell Cancer Vaccine
Figure 78. Dendritic Cell Cancer Vaccine Industrial Chain
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source
